You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
In vitro and in vivo evaluation of elephant p53 (EP53) protein nanoparticles for pediatric osteosarcoma
SBC: Peel Therapeutics, Inc Topic: 102PROJECT SUMMARY ABSTRACT PEEL TherapeuticsIncis a life sciences company created to impact the lives of people with cancerBased on the research efforts of DrJoshua Schiffman and DrAvi SchroederPEEL TherapeuticsPEELhas created liposomal nanoparticles that have been loaded with elephant pEPproteins as a new class of anti cancer protein therapeuticsElephants have an unexpectedly low rate of cancer giv ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
APPSPIRE: expanding the reach of an innovative tobacco control program for youth
SBC: Radiant Creative Group, LLC Topic: NIDADESCRIPTION (provided by applicant): Mobile phone technology offers a variety of opportunities for innovative approaches to health communication and intervention. These opportunities have been amplified by the emergence of next-generation smartphone devices that are capable of rich multimedia and sophisticated interactivity. Smartphone-based programs can be integrated seamlessly into a user's ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Contractile Hydrogel Dressing for Primary Wound Closure
SBC: LYNNTECH INC Topic: NIDDKDESCRIPTION (provided by applicant): Acute and chronic wounds such as diabetic foot ulcers represent a major area of medical concern. With roughly 27 million patients suffering from these types of partial thickness wounds, representing substantial billions in medical expenses, a means to rapidly close such acute and chronic wounds with minimal medical staff involvement would be a major new bre ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule targeting of NADPH oxidase in neutrophils
SBC: P2D, INC Topic: NHLBIDESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Stimuli Responsive Topical Gels for Mechanically Assisted Wound Debridement
SBC: LYNNTECH INC Topic: NIGMSDESCRIPTION (provided by applicant): Debridement of dead, damaged and/or infected tissue from thermal burn wounds and a certain subset of ischemic and necrotic diabetic foot wounds is a commonly utilized wound preparation modality before the application of fillers, dressings or grafts. The existing wound debridement techniques have serious issues such as invasiveness and impreciseness, painful ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice
SBC: Yecuris Corporation Topic: NCRRDESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Development and Production of Standardized Reference Diets for Zebrafish Research
SBC: Meridian Biotech, LLC Topic: 101The over arching goal of this Phase I SBIR proposal is to begin to optimize and implement standard reference diets for the ZebrafishDanio rerioan animal model of critical importance to the understanding of human health and development of vertebrate organismsA key problem in the industry is that standardized diets or feed management strategies have not been developed for Danio rerioThese diets are ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAIn the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral gene therapy for mucopolysaccharidosis
SBC: LENTIGEN CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeting endothelial arginase to treat diabetes-associated vascular dysfunction
SBC: ARGINETIX, INC. Topic: NHLBIDESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health